نتایج جستجو برای: mdm2 protein

تعداد نتایج: 1237193  

Journal: :Cancer research 2009
Xin-Zi Chi Jiyeon Kim Yong-Hee Lee Jung-Won Lee Kyeong-Sook Lee Heejun Wee Wun-Jae Kim Woo-Yoon Park Byung-Chul Oh Gary S Stein Yoshiaki Ito Andre J van Wijnen Suk-Chul Bae

The p14(ARF)-MDM2-p53 pathway constitutes an effective mechanism for protecting cells from oncogenic stimuli such as activated Ras and Myc. Importantly, Ras activation induces p14(ARF) and often occurs earlier than p53 inactivation during cancer development. Here, we show that RUNX3, a tumor suppressor in various tumors including stomach, bladder, colon, and lung, is stabilized by Ras activatio...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2000
E Kobet X Zeng Y Zhu D Keller H Lu

p300 acetylates and activates the tumor suppressor p53 after DNA damage. Here, we show that MDM2, a negative-feedback regulator of p53, inhibited p300-mediated p53 acetylation by complexing with these two proteins. First, we purified a p300-MDM2-p53 protein complex from HeLa nuclear extracts, which was inactive in p53 acetylation, but active in histone acetylation. Also, wild-type, but not N-te...

Journal: :Cell 2004
Dimitris P Xirodimas Mark K Saville Jean-Christophe Bourdon Ronald T Hay David P Lane

The only reported role for the conjugation of the NEDD8 ubiquitin-like molecule is control of the activity of SCF ubiquitin ligase complexes. Here, we show that the Mdm2 RING finger E3 ubiquitin ligase can also promote NEDD8 modification of the p53 tumor suppressor protein. Mdm2 is itself modified with NEDD8 with very similar characteristics to the autoubiquitination activity of Mdm2. By using ...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه تبریز - دانشکده علوم انسانی و اجتماعی 1389

mdm2 آنکوژنی می باشد که پروتئین کد شده توسط آن یک فسفو پروتئین است که با عملکرد یوبی کوئیتین لیگازی باعث ممانعت از فعالیت p53 و پیش برندگی تخریب آن می باشد. p53 یک مهار کننده سرطان می باشد که فعالیت آن در بسیاری از سرطان های انسانی به علت جهش در خود ژن p53 یا انحرافاتی در بیان پروتئین های عمل کننده در مسیر p53 از قبیل mdm2 ممکن است از بین رفته یا به شدت تضعیف گردد. اخیرا یک جانشینی t به g در پر...

2015
Eva Tonsing-Carter Barbara J. Bailey M. Reza Saadatzadeh Jixin Ding Haiyan Wang Anthony L. Sinn Kacie M. Peterman Tiaishia K. Spragins Jayne M. Silver Alyssa A. Sprouse Taxiarchis M. Georgiadis T. Zachary Gunter Eric C. Long Robert E. Minto Christophe C. Marchal Christopher N. Batuello Ahmad R. Safa Helmut Hanenberg Paul R. Territo George E. Sandusky Lindsey D. Mayo Christine M. Eischen Harlan E. Shannon Karen E. Pollok

Triple-negative breast cancers (TNBC) are typically resistant to treatment, and strategies that build upon frontline therapy are needed. Targeting themurine doubleminute 2 (Mdm2) protein is an attractive approach, as Mdm2 levels are elevated in many therapy-refractive breast cancers. The Mdm2 protein–protein interaction inhibitor Nutlin-3a blocks the binding of Mdm2 to key signaling molecules s...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Yen-An Tang Ruo-Kai Lin Yo-Ting Tsai Han-Shui Hsu Yi-Chieh Yang Chih-Yi Chen Yi-Ching Wang

PURPOSE Overexpression of DNA 5'-cytosine-methyltransferase 3A (DNMT3A), which silences genes including tumor suppressor genes (TSG), is involved in many cancers. Therefore, we examined whether the transcriptional deregulation of RB/MDM2 pathway was responsible for DNMT3A overexpression and analyzed the therapeutic potential of MDM2 antagonist for reversing aberrant DNA methylation status in lu...

Journal: :Molecular cancer therapeutics 2015
Eva Tonsing-Carter Barbara J Bailey M Reza Saadatzadeh Jixin Ding Haiyan Wang Anthony L Sinn Kacie M Peterman Tiaishia K Spragins Jayne M Silver Alyssa A Sprouse Taxiarchis M Georgiadis T Zachary Gunter Eric C Long Robert E Minto Christophe C Marchal Christopher N Batuello Ahmad R Safa Helmut Hanenberg Paul R Territo George E Sandusky Lindsey D Mayo Christine M Eischen Harlan E Shannon Karen E Pollok

Triple-negative breast cancers (TNBC) are typically resistant to treatment, and strategies that build upon frontline therapy are needed. Targeting the murine double minute 2 (Mdm2) protein is an attractive approach, as Mdm2 levels are elevated in many therapy-refractive breast cancers. The Mdm2 protein-protein interaction inhibitor Nutlin-3a blocks the binding of Mdm2 to key signaling molecules...

2013
Gilberto Jaramillo-Rangel Marta Ortega-Martínez Julio Sepúlveda-Saavedra Odila Saucedo-Cárdenas Roberto Montes-de-Oca-Luna

PURPOSE p53 is a transcription factor that plays an important role in preventing cancer development. p53 participates in relevant aspects of cell biology, including apoptosis and cell cycle control and must be strictly regulated to maintain normal tissue homeostasis. p53 E3 ubiquitin protein ligase homolog (Mdm2) is an important negative regulator of p53. The purpose of this study was to determ...

Journal: :EMBO reports 2009
Deng Chen Jianbing Zhang Mao Li Elizabeth R Rayburn Hui Wang Ruiwen Zhang

The mouse double minute 2 (MDM2)-p53 interaction regulates the activity of p53 and is a potential target for human cancer therapy. Here, we report that RYBP (RING1- and YY1-binding protein), a member of the polycomb group (PcG), interacts with MDM2 and decreases MDM2-mediated p53 ubiquitination, leading to stabilization of p53 and an increase in p53 activity. RYBP induces cell-cycle arrest and ...

2014
Mei Liu Su-jun Zheng Yu Chen Ning Li Peng-fei Ren Li-ping Dai Zhong-ping Duan Jian-Ying Zhang

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Although new therapeutic strategies have been continuously developed and applied to clinical treatment for HCC, the prognosis is still very poor. Thus, early detection of HCC may enhance effective and curative management. In this study, autoantibody responses to MDM2 protein in HCC patient's serum were evaluated by en...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید